Hepion Pharmaceuticals, Inc.(NASDAQ : HEPA)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.06%||167.67||0.7%||$1125.22m|
|LLY||Eli Lilly & Co.||2.24%||317.25||1.1%||$802.70m|
|MRK||Merck & Co., Inc.||0.44%||90.99||0.7%||$796.41m|
|BMY||Bristol-Myers Squibb Co.||0.56%||74.54||1.0%||$649.52m|
|SIGA||SIGA Technologies, Inc.||1.89%||24.78||0.0%||$473.03m|
|GBT||Global Blood Therapeutics, Inc.||0.01%||67.01||5.6%||$332.78m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-2.26%||222.99||8.2%||$270.27m|
|HZNP||Horizon Therapeutics Plc||-3.67%||61.73||5.4%||$212.46m|
|KRTX||Karuna Therapeutics, Inc.||-1.12%||260.74||0.0%||$202.73m|
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.